AMSEL MEDICAL CORPORATION — Department of Defense SBIR Phase I: AF192-001

Description

Junctional hemorrhage precludes the use of externally applied tourniquets in extremity and proximal cervical injuries at the base of the neck. It is responsible for >60% of deaths in military trauma, with >90% of fatalities occurring in the prehospital environment despite the presence of an on-site medic. To address the unique challenges associated with trauma, especially junctional hemorrhage, Amsel Medical has developed a unique family of rapid needle delivered (18G) site specific mechanical clamping solutions to provide permanent or temporary occlusion of vessels proximal to a bleeding site. Amsel’s ScureClamp™ permanent occluder provides rapid (<30 seconds) hemorrhage control to minimize blood loss and eliminate the need for cutdown, and is removed at the time of the subsequent surgical intervention for wound repair. Amsel has further developed the Scure Temporary Occluder ScureTO™ to enable temporary occlusion and variable flow control to further minimize the risks of local vessel thrombosis and distal prolonged ischemia with its accompanying morbid metabolic effects and enable simple removal when no longer required, without injury to the vessel and without the need for any open surgical procedure or repair. This temporary occlusion device functions as an adjustable and removable internal tourniquet.